TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion

Orsolya Giricz, Veronica Calvo, Esther A. Peterson, Christiane M. Abouzeid, Paraic A. Kenny

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The epidermal growth factor receptor (EGFR) is frequently expressed in triple-negative breast cancer (TNBC) and is a marker of poor prognosis in this patient population. Because activating mutations in this kinase are very rare events in breast cancer, we screened breast tumor gene expression profiles to examine the distribution of EGFR ligand expression. Of the six known EGFR ligands, transforming growth factor alpha (TGFα) was expressed more highly in triple-negative breast tumors than in tumors of other subtypes. TGFα is synthesized as a transmembrane precursor requiring tumor necrosis factor alpha converting enzyme (TACE)/ADAM17-dependent proteolytic release to activate its receptor. In our study, we show that an inhibitor of this proteolytic release blocks invasion, migration and colony formation by several TNBC cell lines. Each of the effects of the drug was reversed upon expression of a soluble TGFα mutant that does not require TACE activity, implicating this growth factor as a key metalloproteinase substrate for these phenotypes. Together, these data demonstrate that TACE-dependent TGFα shedding is a key process driving EGFR activation and subsequent proliferation and invasion in TNBC cell lines.

Original languageEnglish (US)
Pages (from-to)2587-2595
Number of pages9
JournalInternational Journal of Cancer
Volume133
Issue number11
DOIs
StatePublished - Dec 1 2013

Fingerprint

Triple Negative Breast Neoplasms
Transforming Growth Factor alpha
Epidermal Growth Factor Receptor
Breast Neoplasms
Ligands
Cell Line
Metalloproteases
Transcriptome
Intercellular Signaling Peptides and Proteins
Phosphotransferases
Phenotype
Mutation
ADAM17 Protein
Pharmaceutical Preparations
Population
Neoplasms

Keywords

  • epidermal growth factor receptor
  • TACE/ADAM17
  • transforming growth factor alpha
  • triple-negative breast cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Giricz, O., Calvo, V., Peterson, E. A., Abouzeid, C. M., & Kenny, P. A. (2013). TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion. International Journal of Cancer, 133(11), 2587-2595. https://doi.org/10.1002/ijc.28295

TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion. / Giricz, Orsolya; Calvo, Veronica; Peterson, Esther A.; Abouzeid, Christiane M.; Kenny, Paraic A.

In: International Journal of Cancer, Vol. 133, No. 11, 01.12.2013, p. 2587-2595.

Research output: Contribution to journalArticle

Giricz, O, Calvo, V, Peterson, EA, Abouzeid, CM & Kenny, PA 2013, 'TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion', International Journal of Cancer, vol. 133, no. 11, pp. 2587-2595. https://doi.org/10.1002/ijc.28295
Giricz, Orsolya ; Calvo, Veronica ; Peterson, Esther A. ; Abouzeid, Christiane M. ; Kenny, Paraic A. / TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion. In: International Journal of Cancer. 2013 ; Vol. 133, No. 11. pp. 2587-2595.
@article{3c383930958345908752de3dba456d6d,
title = "TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion",
abstract = "The epidermal growth factor receptor (EGFR) is frequently expressed in triple-negative breast cancer (TNBC) and is a marker of poor prognosis in this patient population. Because activating mutations in this kinase are very rare events in breast cancer, we screened breast tumor gene expression profiles to examine the distribution of EGFR ligand expression. Of the six known EGFR ligands, transforming growth factor alpha (TGFα) was expressed more highly in triple-negative breast tumors than in tumors of other subtypes. TGFα is synthesized as a transmembrane precursor requiring tumor necrosis factor alpha converting enzyme (TACE)/ADAM17-dependent proteolytic release to activate its receptor. In our study, we show that an inhibitor of this proteolytic release blocks invasion, migration and colony formation by several TNBC cell lines. Each of the effects of the drug was reversed upon expression of a soluble TGFα mutant that does not require TACE activity, implicating this growth factor as a key metalloproteinase substrate for these phenotypes. Together, these data demonstrate that TACE-dependent TGFα shedding is a key process driving EGFR activation and subsequent proliferation and invasion in TNBC cell lines.",
keywords = "epidermal growth factor receptor, TACE/ADAM17, transforming growth factor alpha, triple-negative breast cancer",
author = "Orsolya Giricz and Veronica Calvo and Peterson, {Esther A.} and Abouzeid, {Christiane M.} and Kenny, {Paraic A.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1002/ijc.28295",
language = "English (US)",
volume = "133",
pages = "2587--2595",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion

AU - Giricz, Orsolya

AU - Calvo, Veronica

AU - Peterson, Esther A.

AU - Abouzeid, Christiane M.

AU - Kenny, Paraic A.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - The epidermal growth factor receptor (EGFR) is frequently expressed in triple-negative breast cancer (TNBC) and is a marker of poor prognosis in this patient population. Because activating mutations in this kinase are very rare events in breast cancer, we screened breast tumor gene expression profiles to examine the distribution of EGFR ligand expression. Of the six known EGFR ligands, transforming growth factor alpha (TGFα) was expressed more highly in triple-negative breast tumors than in tumors of other subtypes. TGFα is synthesized as a transmembrane precursor requiring tumor necrosis factor alpha converting enzyme (TACE)/ADAM17-dependent proteolytic release to activate its receptor. In our study, we show that an inhibitor of this proteolytic release blocks invasion, migration and colony formation by several TNBC cell lines. Each of the effects of the drug was reversed upon expression of a soluble TGFα mutant that does not require TACE activity, implicating this growth factor as a key metalloproteinase substrate for these phenotypes. Together, these data demonstrate that TACE-dependent TGFα shedding is a key process driving EGFR activation and subsequent proliferation and invasion in TNBC cell lines.

AB - The epidermal growth factor receptor (EGFR) is frequently expressed in triple-negative breast cancer (TNBC) and is a marker of poor prognosis in this patient population. Because activating mutations in this kinase are very rare events in breast cancer, we screened breast tumor gene expression profiles to examine the distribution of EGFR ligand expression. Of the six known EGFR ligands, transforming growth factor alpha (TGFα) was expressed more highly in triple-negative breast tumors than in tumors of other subtypes. TGFα is synthesized as a transmembrane precursor requiring tumor necrosis factor alpha converting enzyme (TACE)/ADAM17-dependent proteolytic release to activate its receptor. In our study, we show that an inhibitor of this proteolytic release blocks invasion, migration and colony formation by several TNBC cell lines. Each of the effects of the drug was reversed upon expression of a soluble TGFα mutant that does not require TACE activity, implicating this growth factor as a key metalloproteinase substrate for these phenotypes. Together, these data demonstrate that TACE-dependent TGFα shedding is a key process driving EGFR activation and subsequent proliferation and invasion in TNBC cell lines.

KW - epidermal growth factor receptor

KW - TACE/ADAM17

KW - transforming growth factor alpha

KW - triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84884909066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884909066&partnerID=8YFLogxK

U2 - 10.1002/ijc.28295

DO - 10.1002/ijc.28295

M3 - Article

C2 - 23729230

AN - SCOPUS:84884909066

VL - 133

SP - 2587

EP - 2595

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 11

ER -